TrialAdvance, Inc. Establishes New Strategy Group Focused on Underrepresented Populations in Clinical Trials: Rebecca Budd to Head Group
CHICAGO — Kathleen B. Drennan, president and CEO of TrialAdvance, Inc., announces the creation of a new strategy group called iDICT (Improving Disparities In Clinical Trials). The iDICT Group will help study sponsors achieve the federal government’s directive to increase participation of underrepresented populations in clinical trials. Rebecca Budd will serve as the group’s managing director and chief strategist.
“Despite the fact that the government issued its strongest recommendations yet about the need to address participation of minorities, women, seniors and other underrepresented populations in clinical trials, few companies have been able to comply,” said Drennan. “Many have not yet incorporated this effort into their protocol development and up-front planning process, leading to inadequate enrollment of these challenging populations. Rebecca Budd’s insight has been developed from years of experience in research and analytics, medical communication and patient recruitment strategy, and she has been successful in developing effective strategies for reaching these difficult-to-enroll subgroups.”
“The motivation to participate in clinical trials differs from subgroup to subgroup,” said Budd. “TrialAdvance’s programs not only help sponsor teams achieve better study participant demographics but also complement Engagement-Training™, our proprietary program designed to help study sites tap into their diverse patient communities.”
Budd uses her unique skill set and experience when working with leading multicultural experts to develop and execute study strategies targeting underrepresented populations. Before joining TrialAdvance, she worked for global companies such as Iris Global Clinical Trial Solutions, the Omnicom Group and Hoffmann-LaRoche, Inc. She has a wide range of therapeutic experience including cardiovascular, endocrinology, virology and neurology.
“There is significant pressure for companies to improve clinical trial participation of women, children, the elderly and diverse racial and ethnic groups today,” noted Budd. “These populations bear a disproportionate burden of many diseases. It is critical for clinical trial sponsors to explore differences in how a disease progresses and how patients respond to treatment. The creation of the iDICT Group solidifies TrialAdvance’s commitment to bring clinical trials to all people.”
Budd received her bachelor’s degree at Southern Methodist University in Dallas and her master of business administration degree at the Kellogg School of Management at Northwestern University in Evanston, Ill.
About TrialAdvance
TrialAdvance is committed to building Super SitesTM, which are high-performing clinical trial investigative sites that perform better, recruit patients faster and complete trials sooner. Super Sites™ are the key to unlocking study delays. TrialAdvance combines its extensive clinical trial experience with that of sponsor teams and sites to devise practical solutions for tackling difficult- to-enroll studies and increasing enrollment of underrepresented populations. TrialAdvance utilizes a proprietary program called Engagement-Training™ to help sponsor teams select stronger sites, create performance-based solutions and optimize patient recruitment and enrollment programs, thereby reducing the need for additional sites, redundant recruitment resources and extended timelines. For more information about TrialAdvance call 312-339-2678 or visit trialadvance.com.
Tags:
